The Biotech Rundown
Monday, July 28, 2014
OXiGENE Inc. May Be A Buyout Target
OXiGene Inc. (OXGN) is primed for a full data readout of the Phase 2 Zyb/Avastin Study. I suspect that this should create Big Pharma interest and drive shares higher soon. Stay tuned!
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment